CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 188 enrolled
Drug / intervention
OPC-12759 Ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00885079
NCT00885079Phase 3Completed
CompareCT.gov

Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Apr 21, 2009·Updated Dec 12, 2013

In Brief

A Phase 3 clinical trial evaluating OPC-12759 Ophthalmic suspension and Hyalein Mini Ophthalmic solution for Dry Eye Syndromes. Completed, enrolled 188 participants across 5 sites.

Detailed Summary

The purpose of this study is to verify whether OPC-12759 ophthalmic suspension is effective compared with active control in dry eye patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 21, 2009
Enrollment StartMay 1, 2009
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.2 years ago

Interventions

OPC-12759 Ophthalmic suspensiondrug

OPC-12759 Ophthalmic suspension 2%

Hyalein Mini Ophthalmic solutiondrug

Hyalein Mini Ophthalmic solution 0.1%